Prosultiamine/ja: Difference between revisions
Prosultiamine/ja
Created page with "プロスルチアミン" Tags: Mobile edit Mobile web edit |
Created page with "<!--Chemical data--> | C=15 | H=24 | N=4 | O=2 | S=2 | smiles = O=CN(\C(=C(\SSCCC)CCO)C)Cc1cnc(nc1N)C }}" |
||
| Line 1: | Line 1: | ||
<languages /> | <languages /> | ||
{{Drugbox | {{Drugbox | ||
| IUPAC_name = ''N''-[(4-amino-2-methylpyrimidin-5-yl)methyl]-''N''-[(1''E'')-4-hydroxy-1-methyl-2-(propyldisulfanyl)but-1-en-1-yl]formamide | | IUPAC_name = ''N''-[(4-amino-2-methylpyrimidin-5-yl)methyl]-''N''-[(1''E'')-4-hydroxy-1-methyl-2-(propyldisulfanyl)but-1-en-1-yl]formamide | ||
| image = Prosultiamine.png | | image = Prosultiamine.png | ||
| alt = | | alt = プロスルチアミンの骨格式 | ||
| width = 240 | | width = 240 | ||
| image2 = Prosultiamine 3D ball.png | | image2 = Prosultiamine 3D ball.png | ||
| alt2 = | | alt2 = プロスルチアミン分子のボール＆スティックモデル | ||
| width2 = 260 | | width2 = 260 | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| tradename = | | tradename = | ||
| Line 19: | Line 15: | ||
| legal_status = Rx-only | | legal_status = Rx-only | ||
| routes_of_administration = [[Mouth|Oral]] | | routes_of_administration = [[Mouth|Oral]] | ||
<!--Pharmacokinetic data--> | <!--Pharmacokinetic data--> | ||
| bioavailability = | | bioavailability = | ||
| Line 27: | Line 21: | ||
| elimination_half-life = | | elimination_half-life = | ||
| excretion = | | excretion = | ||
<!--Identifiers--> | <!--Identifiers--> | ||
| CAS_number = 59-58-5 | | CAS_number = 59-58-5 | ||
| Line 38: | Line 30: | ||
| UNII_Ref = {{fdacite|correct|FDA}} | | UNII_Ref = {{fdacite|correct|FDA}} | ||
| UNII = UI32MM3XE3 | | UNII = UI32MM3XE3 | ||
<!--Chemical data--> | <!--Chemical data--> | ||
| C=15 | H=24 | N=4 | O=2 | S=2 | | C=15 | H=24 | N=4 | O=2 | S=2 | ||
| smiles = O=CN(\C(=C(\SSCCC)CCO)C)Cc1cnc(nc1N)C | | smiles = O=CN(\C(=C(\SSCCC)CCO)C)Cc1cnc(nc1N)C | ||
}} | }} | ||
<div lang="en" dir="ltr" class="mw-content-ltr"> | <div lang="en" dir="ltr" class="mw-content-ltr"> | ||
Revision as of 10:41, 3 April 2024
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C15H24N4O2S2 |
| Molar mass | 356.50 g·mol−1 |
| 3D model (JSmol) | |
| |
Prosultiamine (INN; also known as thiamine propyl disulfide or TPD; brand name Jubedel,) is a disulfide thiamine derivative discovered in garlic in Japan in the 1950s, and is similar to allithiamine. It was developed as a treatment for vitamin B1 deficiency. It has improved lipid solubility relative to thiamine and is not rate-limited by dependency on intestinal transporters for absorption, hence the reasoning for its development.
Research
It has been studied as a potential treatment for infection with human T-lymphotropic virus (HTLV), since it has been shown to reduce viral load and symptoms.
See also
 | この記事は、クリエイティブ・コモンズ・表示・継承ライセンス3.0のもとで公表されたウィキペディアの項目Prosultiamine/ja(2 March 2024編集記事参照)を素材として二次利用しています。 Lua error in Module:Itemnumber at line 91: attempt to concatenate local 'qid' (a nil value). |